
|Articles|December 22, 2011
Dr. Susan Urba Discusses Cost Concerns for Treatment of Chemotherapy-Induced Nausea
Advertisement
In this segment, Dr. Susan Urba, University of Michigan, Comprehensive Cancer Center, talks about treatment guidelines and decisions relevant to chemotherapy-induced nausea and vomiting (CINV) in a managed care setting.
In addition, Dr. Urba warns of the consequences associated with the treatment of CINV when cost concerns impact best practices. Often, these consequences can include increased costs from uncontrolled symptoms and potential hospital admission due to dehydration.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Ebola Cases Top 1700 as Unpaid Health Workers Strike
2
FDA Approves Atacicept for IgA Nephropathy
3
340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs
4
Quest Adds Haystack MRD to OncoEMR for Community Oncology
5




